In 201 patients aged 5-65 with birch pollen SCIT, a one-strength accelerated escalation caused more adverse drug reactions than the standard regimen (48.5% vs 32.0%), mostly local and mild; 9 systemic reactions, all WAO grade 1-2, and none serious.
RCTn = 201
Jutel et al. A One-Strength Dose Escalation Regimen for Birch Pollen Subcutaneous Immunotherapy Is Safe and Tolerable in Children, Adolescents, and Adults